We first reported saporin-conjugated anti-epidermal growth factor receptor (EGFR) antibody target EGFR (cetuximab) (IT-Cmab), NPe6, and light (664 nm) irradiation (i.e., iTAP) in lung cancer cells in 2022. This evidence concerns the gene EGFR and lung carcinoma.